Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04829383 · ClinicalTrials.gov registry record · Phase 2
A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma
A Phase 2 study of Unresectable Hepatocellular Carcinoma, sponsored by Howard S Hochster.
- Active
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 7
- Study locations
NCT04829383 is a Phase 2 study of Unresectable Hepatocellular Carcinoma that is active but no longer recruiting, run by Howard S Hochster. The registered enrollment target is 50 participants, below the 82-participant average among 12 other Unresectable Hepatocellular Carcinoma trials with a reported enrollment target (39% lower). The trial reports 7 study locations across 7 states.
The verdict
NCT04829383, a Phase 2 study of Unresectable Hepatocellular Carcinoma, is active but no longer recruiting, sponsored by Howard S Hochster.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 7
- Study locations
Study Summary
This will be a nonrandomized, single arm feasibility study with the primary goal of evaluating the safety profile of the combination of atezolizumab and bevacizumab in patients with advanced/metastatic HCC with Child-Pugh B7 and B8 liver disease who have received no prior systemic therapy.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Atezolizumab
Study Locations (7)
Illinois
- University of Illinois Cancer Center - Chicago
Indiana
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center - Indianapolis
Nebraska
- University of Nebraska Medical Center - Omaha
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
New York
- New York University Clinical Cancer Center - New York
Texas
- DHR Health Institute for Research and Development - Edinburg
Wisconsin
- Univeristy of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2021-03-22 |
| Est. Completion | 2025-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04829383
The ClinicalTrials.gov registry entry for NCT04829383 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 82-participant average among 12 other Unresectable Hepatocellular Carcinoma trials with a reported enrollment target (39% lower). The listed sponsor is Howard S Hochster, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Unresectable Hepatocellular Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Bevacizumab is the first listed.
NCT04829383 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Illinois, Indiana, Nebraska.
Frequently Asked Questions
What is clinical trial NCT04829383 about?
NCT04829383 is a clinical study titled "A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma". This will be a nonrandomized, single arm feasibility study with the primary goal of evaluating the safety profile of the combination of atezolizumab and bevacizumab in patients with advanced/metastatic HCC with Child-Pugh B7 and B8 liver disease who have received no prior systemic therapy.
What is the current status of trial NCT04829383?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2021-03-22. Estimated completion is 2025-10.
What conditions does trial NCT04829383 study?
This clinical trial studies the following conditions: Unresectable Hepatocellular Carcinoma.
What interventions are being tested in trial NCT04829383?
The interventions under investigation include: Bevacizumab (DRUG), Atezolizumab (DRUG).
Who is sponsoring clinical trial NCT04829383?
This trial is sponsored by Howard S Hochster, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04829383 being conducted?
This trial has 7 study locations across Illinois, Indiana, Nebraska, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Unresectable Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
RECRUITING · Phase 2
-
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
RECRUITING · Phase 2
-
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
RECRUITING · Phase 2
-
68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer
COMPLETED · Phase 2
-
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
RECRUITING · Phase 1
-
Atezolizumab+Bevacizumab+SBRT in Unresectable HCC
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.